Golicitinib combined with Pomadomide

Phase 2Small molecule

Golicitinib combined with Pomadomide is one of 5 small molecule programs targeting Pomalidomide. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PomalidomideRecruiting

PomalidomidePhase 2

Recruiting

Competition

Competitive Landscape

4 competitors in Pomalidomide

#DrugCompanyPhaseTrials

Pomalyst

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

11 2

Trexall

Jazz Pharmaceuticals

Phase 2

1 3

Rituxan

Roche

Phase 2

1 4

Nublexa

BBeijing InnoCare Pharma Tech Co., Ltd.

Phase 2

1 5

Golicitinib combined with Pomadomide

SSun Yat-sen University

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Recruiting

Pomalidomide

NCT06855823

Clinical

Trials by Indication[1]

Pomalidomide1 trial

A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL

Recruiting·SSun Yat-sen University·Phase 1/2·NCT06855823·33 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Golicitinib combined with Pomadomide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Golicitinib combined with Pomadomide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Golicitinib combined with Pomadomide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sun Yat-sen University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSun Yat-sen University

Golicitinib combined with Pomadomide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Pomalidomide1 trial

References

Drug Info

Quick Facts

Related News